Arbutus Biopharma (ABUS) said Tuesday it has named Lindsay Androski as chief executive, effective immediately.
The company said Androski succeeds interim CEO and President Michael J. McElhaugh, and will join the company's board.
Androski is a special counsel at Genevant, Arbutus said.
All existing board members have stepped down from their roles, Arbutus said, adding that four new members, in addition to Androski, have been added.
Price: 3.55, Change: +0.21, Percent Change: +6.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.